Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Siglec-9, a Putative Immune Checkpoint Marker for Cancer Progression Across Multiple Cancer Types

17 Mar 2022

Abstract excerpt

Siglec-9, a cell surface transmembrane receptor mainly expressed on B cells, CD56+ NK cells, and CD4+ and CD8+ T cells, is strongly related to the tumor immune microenvironment. However, the expression pattern of Siglec-9 and its prognostic potential have not been investigated in a pan-cancer perspective. This study aimed to explore the association of Siglec-9 with prognosis, tumor stage, molecular subtype, and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Ferroptosis and cancer prognosis
Share to Immune cells in cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35372497
DOI: 10.3389/fmolb.2022.743515

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Siglec-9, a Putative Immune Checkpoint Marker for Cancer Progression Across Multiple Cancer TypesPMID 35372497Read ↗

Tumor Derived SIGLEC Family Genes May Play Roles in Tumor Genesis, Progression, and Immune Microenvironment RegulationSemantic proximity Read ↗

Siglec10 as an Immunosuppressive and Tumorgenesis Signature for Prediction of Survival Prognosis in GliomasSemantic proximity Read ↗

Siglec10 as an Immunosuppressive and Tumorgenesis Signature for Prediction of Survival Prognosis in GliomasSemantic proximity Read ↗

Bioinformatics investigation of the prognostic value and mechanistic role of CD9 in glioma.Semantic proximity Read ↗

The epiphany derived from T-cell–inflamed profiles: Pan-cancer characterization of CD8A as a biomarker spanning clinical relevance, cancer prognosis, immunosuppressive environment, and treatment responsesSemantic proximity Read ↗

Pan-Cancer Analysis Revealed SRSF9 as a New Biomarker for Prognosis and ImmunotherapySemantic proximity Read ↗

Lymphocyte Antigen 9 as a potential immunotherapeutic target and a new prognostic biomarker for lung adenocarcinomaSemantic proximity Read ↗

Unravelling CD24 ‐ Siglec‐10 pathway: Cancer immunotherapy from basic science to clinical studiesSemantic proximity Read ↗

Integrative Analysis of the Expression of SIGLEC Family Members in Lung Adenocarcinoma via Data MiningSemantic proximity Read ↗

Innate immune checkpoint Siglec10 in cancers: mining of comprehensive omics data and validation in patient samplesSemantic proximity Read ↗

The prognostic and immune significance of SLAMF9 in pan-cancer and validation of its role in colorectal cancerSemantic proximity Read ↗

APOBEC3C Served as a Novel Immune-Related Prognosis Biomarker in Glioma: A Pan-Cancer AnalysisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.